AstraZeneca (LSE:AZN) sat at the centre of the day's health and biotech news, both as the source of a landmark FDA approval and as the anchor of a new commercial relationship that sent CelLBxHealth (AIM:CLBX) sharply higher. Governance change at Avacta (AIM:AVCT) added to a busy session for the sector.
CelLBxHealth named AstraZeneca qualified service provider
CelLBxHealth (AIM:CLBX) has been designated a qualified service provider to AstraZeneca under a Master Services Agreement, giving the company a mandate to analyse clinical trial samples using its proprietary Parsortix® circulating tumour cell platform. The agreement represents a meaningful commercial validation of the technology, and the shares responded accordingly, rising 23.9% to 2.1372p.
The Parsortix® platform isolates intact circulating tumour cells from blood, and its inclusion in AstraZeneca's clinical infrastructure positions CelLBxHealth as a direct participant in large-scale oncology trial workflows. The tie-up with one of the world's largest pharmaceutical companies gives the business both revenue visibility and a high-profile reference customer.
Avacta appoints Richard Hughes as non-executive chairman
Avacta Group (AIM:AVCT) named Richard Hughes as its incoming non-executive Chairman, with the appointment taking effect following the Annual General Meeting on 22 June. Hughes joins as Avacta continues to advance its affimer-based therapeutics pipeline, and the board change was received positively, lifting the shares 5.15% to 79.39p.
The appointment follows the earlier announcement of Christina Coughlin and Shaun Chilton joining the board, completing a significant refresh of Avacta's non-executive leadership ahead of what the company expects to be a pivotal period for its clinical programmes.
FDA clears AstraZeneca's Imfinzi in early-stage bladder cancer
AstraZeneca (LSE:AZN) secured US regulatory approval for Imfinzi (durvalumab) in combination with BCG for adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer, a setting where treatment options have historically been The FDA clearance was supported by data from the Phase III POTOMAC trial, which demonstrated a 32% reduction in the risk of disease recurrence, progression or death. AstraZeneca shares edged 0.55% higher to 13,812p.
The approval extends Imfinzi's reach beyond its established indications in lung and biliary tract cancers, opening a new patient population in early-stage urothelial disease. Neal Shore was among the clinical investigators cited in connection with the POTOMAC programme. The decision adds to AstraZeneca's growing oncology franchise and reinforces durvalumab's commercial trajectory in the US market.
